Phase 2 Obesity Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are in a normal heart rhythm (called sinus rhythm) at the time of joining the trial
• People aged 18 to 80 years old
• People with a Body Mass Index (BMI) between 27 and 60
• People who have been diagnosed with atrial fibrillation (an irregular heartbeat), confirmed by a heart tracing (ECG) or heart monitor, who experience symptoms from it, and whose atrial fibrillation is either occasional (paroxysmal) or ongoing (persistent)
• People whose diabetes medications (including insulin, if taken) have not changed for at least 3 months before joining
• People with Type 2 Diabetes who have an HbA1c (a blood sugar control measure) of 10% or below
• People who are willing and able to self-administer the study medication, follow all study requirements, and sign a consent form

Who may not be able to join:

• People who have had a procedure to treat atrial fibrillation (ablation) within the last 6 months
• People who have a planned ablation procedure scheduled within 3 months after joining the trial
• People who have significant heart valve disease and are scheduled for heart valve surgery or intervention within the next 12 months
• People with severe, uncontrolled heart or lung disease
• People whose heart failure is classified as a more serious stage (New York Heart Association Class III or IV) (confirm with trial site)
• People whose heart pumping function is significantly reduced (left ventricular ejection fraction below 35%) at the time of screening
• People who have been hospitalised in the past 6 months for a heart attack, unstable chest pain (angina), stroke, mini-stroke (transient ischemic attack), or heart surgery
• People who have had a solid organ transplant (such as a kidney, liver, or heart transplant)
• People with Type 1 diabetes or autoimmune diabetes
• People with significantly reduced kidney function or who are on dialysis
• People with advanced liver scarring (cirrhosis) with serious complications such as fluid build-up, brain problems related to liver disease, high blood pressure in the liver's blood vessels, or swollen veins in the oesophagus
• People with a low haemoglobin (red blood cell) level below 9 g/dL (a measure of anaemia)
• People currently participating in another clinical trial, or who have taken part in a drug or device trial within the last 3 months
• People with significantly elevated liver enzyme levels (above 300 U/L)
• People who report drinking, on average, more than 2 alcoholic drinks per day
• People with an active cancer diagnosis (except certain minor skin cancers)
• People whose life expectancy is less than 3 years due to other serious health conditions
• People with significant mental health conditions, psychological disorders, or substance use disorders that would affect their suitability for the study
• People with any other serious condition that, in the study doctor's judgment, puts them at undue risk from participating
• People who plan to move away from the Northeast Ohio area within the next 12 months
• People with a personal or family history of pancreatitis (inflamed pancreas), medullary thyroid cancer, or a condition called Multiple Endocrine Neoplasia Type 2 (MEN2)
• People who are currently using, or have used within the last 6 months, certain diabetes or weight-related medications known as GLP-1, DPP4 inhibitors, or GIP/GLP-1 combination therapies (confirm with trial site for specific medication names)
• People who have had a known allergic reaction to similar medications used in this trial
• People with an allergy to medical-grade tape or adhesive
• People who are pregnant, breastfeeding, or planning to become pregnant

Important: Always verify eligibility with the trial site directly before applying.